click below
click below
Normal Size Small Size show me how
Cardio 1 Drugs 2
| Generic | Brand | Indication | Class | MOA | Dose | Black Box Warning |
|---|---|---|---|---|---|---|
| Amlodipine | Norvasc | Hypertension | Calcium Channel Blocker, Dihydropyridine | inhibits L-type Ca2+ channels in vascular smooth muscle (thus leading to vasodilation) and cardiac cells (thus decreased cardiac contractility); but is vascular selective | 2.5 - 10 mg PO once daily | None |
| Amlodopine and Benazepril | Lotrel | Hypertension | Calcium Channel Blocker, Dihydropyridine + Angiotensin-Converting Enzyme (ACE) inhibitor | inhibit L-type Ca2+ channels in vascular smooth muscle (thus leading to vasodilation) and cardiac cells (thus decreased cardiac contractility); but is vascular selective; also inhibits conversion of angiotensin I to angiotensin II | Amlodipine 2.5 - 10 mg/ Benazepril 10 - 40 mg PO once daily | Fetal toxicity |
| Bumetanide | Bumex | Edema or volume overload | Loop diuretic | inhibits the Na+K+2Cl- transport protein @ thick ascending loop of Henle, thus inhibiting reabsorption of Na+ and Cl- | 0.5 -2 mg PO/IV once daily | Fluid/electrolyte loss |
| Chlorthalidone | Hygroton | Hypertension | Thiazide-related diuretic | inhibit Na+Cl- cotransporter @ distal convoluted tubule, this inhibiting Na+ reabsorption and causing increased Na+ and water excretion | 12.5 - 25 mg PO once daily | None |
| Diltiazem | Cardizem, Cardizem CD, Cardizem LA, Cartia XT | Atrial fibrillation | Calcium Channel Blocker, Nondihydropyridine Antiarrhythmic Agent, Class IV | inhibit L-type Ca2+ channels in vascular smooth muscle (thus leading to vasodilation) and cardiac cells (thus decreased cardiac contractility); but is cardiac selective | IR: 120 - 480 mg per day in 3-4 divided doses ER: 120 - 480 mg PO per day in 1-2 divided doses | None |
| Furosemide | Lasix | Edema or volume overload | Loop diuretic | inhibits the Na+K+2Cl- transport protein @ thick ascending loop of Henle, thus inhibiting reabsorption of Na+ and H2O, leading to diuresis | 20 - 80 mg PO once daily | Fluid/electrolyte loss |
| Hydrochlorothiazide | Microzide | Hypertension | Thiazide diuretic | inhibit Na+Cl- cotransporter @ distal convoluted tubule, thus inhibiting Na+ reabsorption and causing increased Na+ and water excretion | 12.5 - 25 mg PO once daily | None |
| Isosorbide mononitrate | Imdur | Angina | Vasodilator | ultimately leads to an increase in cGMP, with subsequent vascular smooth muscle cell relaxation and vasodilation; preferentially dilates veins, but also dilates arteries and leads to a decrease in myocardial workload | IR: 5 - 20 mg PO BID ER: 30 - 120 mg PO once daily | None |
| Lisinopril and Hydrochlorothiazide | Zestoretic | Hypertension | Angiotensin II Receptor Blocker (ARB) + Thiazide diuretic | inhibits conversion of angiotensin I to angiotensin II and inhibits Na+Cl- cotransporter @ distal convoluted tubule, this inhibiting Na+ reabsorption and causing increased Na+ and water excretion | Lisinopril 10-20 mg/Hydrochlorothiazide 12.5 - 25 mg PO once daily | Fetal toxicity |
| Nifedipine | Procardia XL, Nifedical, Adalat XL | Hypertension | Calcium Channel Blocker, Dihydropyridine | inhibits L-type Ca2+ channels in vascular smooth muscle (thus leading to vasodilation) and cardiac cells (thus decreased cardiac contractility); but is vascular selective | ER: 30 - 90 mg PO once daily | None |
| Nitroglycerin | Nitrostat | Angina | Vasodilator | bioactivated to release NO in vascular smooth muscle cells; leads to increase in cGMP, subsequent vascular smooth muscle cell relaxation and vasodilation; preferentially dilates veins, also dilates arteries, leads to a decrease in myocardial workload | SL tab: Dissolve 0.4 mg sublingually at the first sign of chest pain; repeat every 5 minutes up to 3 doses | None |
| Spironolactone | Aldactone | Heart failure with reduced ejection fraction | Potassium Sparing Diuretic, Mineralocorticoid (aldosterone) Receptor Antagonist | antagonist of the mineralocorticoid receptor @ the collecting duct, thus increasing Na+, Cl- and water excretion, while conserving K+ and H+ ions | 12.5 - 50 mg PO once daily | None |
| Toresemide | Demadex | Edema or volume overload | Loop diuretic | inhibits the Na+K+2Cl- transport protein @ thick ascending loop of Henle, thus inhibiting reabsorption of Na+ and H2O, leading to diuresis | 5 - 50 mg PO once daily | None |
| Triamterine and Hydrochlorothiazide | Dyazide, Maxzide | Hypertension | Potassium Sparing Diuretic + Thiazide Diuretic | Inhibits Na+reabsorption via epithelial Na+ channel @ collecting duct, and inhibits Na+Cl- cotransporter @ distal convoluted tubule, thus inhibiting Na+ reabsorption and causing increased Na+ and water excretion | Hydrochlorothiazide 25 - 50 mg/Triamterene 37.5 - 75 mg PO once daily | Hyperkalemia |
| Verapamil | Calan SR, Verelan, Verelan PM | Atrial fibrillation | Calcium Channel Blocker, Nondihydropyridine Antiarrhythmic Agent, Class IV | inhibits L-type Ca2+ channels in vascular smooth muscle (thus leading to vasodilation) and cardiac cells (thus decreased cardiac contractility); but is cardiac selective | IR: 120 - 480 mg PO per day in 3-4 divided doses ER: 120 - 480 mg PO once daily | None |
| Losartan and Hydrochlorothiazide | Hyzaar | Hypertension | Angiotensin II Receptor Blocker (ARB) + Thiazide diuretic | selective antagonist of the angiotensin II type 1 receptor (AT1R) and inhibits Na+Cl- cotransporter @ distal convoluted tubule, thus inhibiting Na+ reabsorption and causing increased Na+ and water excretion | Losartan 50-100 mg/Hydrochlorothiazide 12.5 - 25 mg PO once daily | Fetal toxicity |